https://www.yiliao.com/index.php?action=history&feed=atom&title=%E8%B6%85%E8%BF%9B%E5%B1%95
超进展 - 版本历史
2026-04-18T01:56:52Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312305&oldid=prev
2026年1月1日 (四) 21:59 77921020
2026-01-01T21:59:27Z
<p></p>
<table class="diff diff-contentalign-left diff-editfont-monospace" data-mw="interface">
<col class="diff-marker" />
<col class="diff-content" />
<col class="diff-marker" />
<col class="diff-content" />
<tr class="diff-title" lang="zh-Hans-CN">
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">←上一版本</td>
<td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">2026年1月1日 (四) 21:59的版本</td>
</tr><tr><td colspan="2" class="diff-lineno" id="mw-diff-left-l154" >第154行：</td>
<td colspan="2" class="diff-lineno">第154行：</td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #475569;">[肺癌数据]：大型回顾性研究，证实在 NSCLC 中，HPD 仅发生于免疫治疗组（约 13.8%），化疗组无此现象。虽然 EGFR 突变患者预后极差，但其 HPD 发生率在该研究中低于 MDM2 扩增者。</span></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> <span style="color: #475569;">[肺癌数据]：大型回顾性研究，证实在 NSCLC 中，HPD 仅发生于免疫治疗组（约 13.8%），化疗组无此现象。虽然 EGFR 突变患者预后极差，但其 HPD 发生率在该研究中低于 MDM2 扩增者。</span></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </p></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </div></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> 超进展 (HPD) · 知识图谱</ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </div></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <tr style="border-bottom: 1px solid #f1f5f9;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">黑名单基因</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="padding: 10px 15px; color: #334155;">[[MDM2]] (扩增) • [[EGFR]] (突变) • [[MDM4]] • [[STK11]] (原发耐药)</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </tr></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <tr style="border-bottom: 1px solid #f1f5f9;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键机制</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="padding: 10px 15px; color: #334155;">[[IFN-γ悖论]] • [[p53失活]] • [[Fc受体]] • [[肿瘤生长速率]] (TGR)</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </tr></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <tr style="border-bottom: 1px solid #f1f5f9;"></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">鉴别诊断</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="padding: 10px 15px; color: #334155;">[[假性进展]] (PsPD) • [[iRECIST]] • [[ctDNA]] (液体活检)</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </tr></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <tr></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">临床管理</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> <td style="padding: 10px 15px; color: #334155;">[[NGS筛查]] • [[立即停药]] • [[挽救性化疗]] • [[EGFR-TKI]]</td></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </tr></ins></div></td></tr>
<tr><td colspan="2"> </td><td class='diff-marker'>+</td><td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div><ins style="font-weight: bold; text-decoration: none;"> </table></ins></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div> </div></div></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"></td></tr>
<tr><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td><td class='diff-marker'> </td><td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div></div></div></td></tr>
</table>
77921020
https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312304&oldid=prev
2026年1月1日 (四) 21:55 77921020
2026-01-01T21:55:24Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312304&oldid=312303">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312303&oldid=prev
2026年1月1日 (四) 21:49 77921020
2026-01-01T21:49:38Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312303&oldid=312301">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312301&oldid=prev
2026年1月1日 (四) 21:41 77921020
2026-01-01T21:41:59Z
<p></p>
<a href="https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312301&oldid=312299">显示更改</a>
77921020
https://www.yiliao.com/index.php?title=%E8%B6%85%E8%BF%9B%E5%B1%95&diff=312299&oldid=prev
77921020：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-01-01T21:34:40Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>超进展</strong> (Hyperprogressive Disease, <strong>HPD</strong>) 是一种与<strong>[[免疫检查点抑制剂]]</strong> (ICI) 治疗相关的反常临床现象，表现为治疗后肿瘤生长动力学发生戏剧性的加速，导致患者病情急剧恶化和生存期显著缩短。与传统的“原发性耐药”不同，HPD 的核心特征是<strong>[[肿瘤生长速率]]</strong> (TGR) 较治疗前显著增加（通常增加 ≥50% 或 ≥2倍）。HPD 在非小细胞肺癌、头颈部鳞癌和胃癌中较为常见，发生率约为 4% 至 29%。其分子机制尚未完全阐明，但<strong>[[MDM2扩增]]</strong>、<strong>[[EGFR突变]]</strong>以及巨噬细胞的 Fc 受体介导效应被认为是关键驱动因素。临床上，必须将 HPD 与<strong>[[假性进展]]</strong> (Pseudoprogression) 严格区分，前者需立即停药，后者则应继续治疗。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible mw-collapsed" style="width: 100%; max-width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">超进展 (HPD)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Hyperprogressive Disease (点击展开)</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
[[Image:HPD_growth_kinetics_curve.png|100px|肿瘤生长动力学曲线对比]]<br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">治疗后斜率陡增</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">现象分类</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">免疫治疗不良事件 (irAE)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">关联药物</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[PD-1抑制剂]] > [[PD-L1抑制剂]] > CTLA-4</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">高危基因</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;"><strong>MDM2扩增</strong>, <strong>MDM4</strong>, <strong>EGFR</strong></td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">发生率</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">4% - 29% (因癌种而异)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">核心指标</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #1e40af;">[[TGK]] Ratio ≥ 2<br>[[TGR]] 增加 ≥ 50%</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">高发人群</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">高龄 (>65岁), 转移负荷大</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">预后影响</th><br />
<td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #b91c1c;">OS 显著缩短 (< 3个月)</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">处理原则</th><br />
<td style="padding: 6px 12px; color: #b91c1c;"><strong>立即停药</strong></td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：免疫系统的“叛变”</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
HPD 的发生是多因素的，目前主流假说认为它涉及免疫微环境的异常重塑和特定癌基因的代偿性激活。<br />
</p><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>Fc 受体介导的巨噬细胞重编程：</strong><br />
<br>许多 PD-1 抗体（如 IgG4 骨架）仍保留与 FcγR 的弱结合力。在 HPD 患者中，抗体可能通过 Fc 段与肿瘤相关巨噬细胞 (TAM) 上的 <strong>[[Fcγ受体]]</strong> 结合，诱导巨噬细胞向免疫抑制型 (<strong>[[M2型]]</strong>) 极化，释放 IL-10 和 VEGF，反而促进了肿瘤血管生成和生长。</li><br />
<li style="margin-bottom: 12px;"><strong>癌基因 MDM2/MDM4 扩增：</strong><br />
<br><strong>[[MDM2]]</strong> 扩增的肿瘤通常伴随 p53 功能丧失。PD-1 阻断可能通过干扰干扰素 (IFN-γ) 通路，异常上调 MDM2 的表达，进而彻底抑制 p53 的抑癌功能，导致肿瘤爆发性生长。这解释了为何 MDM2 扩增患者禁用 ICI。</li><br />
<li style="margin-bottom: 12px;"><strong>代偿性检查点上调：</strong><br />
<br>阻断 PD-1 可能导致效应 T 细胞发生“耗竭代偿”，迅速上调其他抑制性受体（如 <strong>[[TIM-3]]</strong>, <strong>[[LAG-3]]</strong>），导致更深层的免疫抑制。</li><br />
</ul><br />
[[Image:HPD_mechanism_macrophage_MDM2.png|100px|Fc受体与MDM2扩增机制]]<br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床鉴别：真伪进展之辨</h2><br />
<div style="background-color: #f0f9ff; border-left: 5px solid #1e40af; padding: 15px 20px; margin: 20px 0; border-radius: 4px;"><br />
<h3 style="margin-top: 0; color: #1e40af; font-size: 1.1em;">生死攸关的判断</h3><br />
<p style="margin-bottom: 0; text-align: justify; font-size: 0.95em; color: #334155;"><br />
临床最大的挑战在于区分 <strong>超进展 (HPD)</strong> 与 <strong>[[假性进展]] (Pseudoprogression)</strong>。前者是真实的恶化，需立即停药；后者是免疫细胞浸润引起的影像学“肿胀”，预后通常较好，需继续用药。<br />
</p><br />
</div><br />
<br />
<div style="overflow-x: auto; margin: 30px auto; max-width: 90%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.95em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 20%;">特征维度</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #b91c1c; width: 40%;">超进展 (HPD)</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #15803d; width: 40%;">假性进展 (PsPD)</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">临床症状</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>显著恶化</strong> (PS评分下降)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">通常稳定或改善</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">发生时间</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">非常早 (通常 < 8周)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">可发生于任何时间 (通常 < 12周)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">肿瘤动力学</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">TGR 激增 (<strong>爆发式</strong>)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">温和增大 (因炎性浸润)</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">ctDNA 水平</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>显著升高</strong></td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">降低或检测不到</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">处理策略</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">立即停药，转为化疗</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">继续治疗，密切随访 (4-8周复查)</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">应对与挽救策略</h2><br />
<p style="margin: 15px 0; text-align: justify;"><br />
一旦确诊或高度怀疑 HPD，必须采取果断措施，因为 HPD 患者如果不及时干预，中位生存期通常不足 3 个月。<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>立即停用免疫药物：</strong> <br />
<br>这是首要原则。继续使用 ICI 只会加速死亡。</li><br />
<li style="margin-bottom: 12px;"><strong>挽救性化疗：</strong><br />
<br>对于 HPD 患者，转为对该肿瘤类型的标准<strong>[[细胞毒性化疗]]</strong>（如紫杉醇、吉西他滨）往往能观察到较好的反应。有理论认为快速增殖的细胞对化疗更敏感。</li><br />
<li style="margin-bottom: 12px;"><strong>早期筛查与规避：</strong><br />
<br>治疗前进行 NGS 检测。对于存在 <strong>[[MDM2扩增]]</strong>、<strong>[[EGFR突变]]</strong> (特别是无 T790M 突变) 或 <strong>[[DNMT3A]]</strong> 突变的患者，应谨慎使用或避免单药免疫治疗。</li><br />
</ul><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Champiat S, et al. (2017).</strong> <em>Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated With Anti-PD-1/PD-L1.</em> <strong>[[Clinical Cancer Research]]</strong>. 2017;23(8):1920-1928.<br><br />
<span style="color: #475569;">[学术点评]：现象定义。首次系统性定义了 HPD 现象，提出了 TGR (肿瘤生长速率) 的比较方法，并指出高龄是潜在风险因素。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Kato S, et al. (2017).</strong> <em>Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Acceleration of Growth Rate.</em> <strong>[[Clinical Cancer Research]]</strong>. 2017;23(15):4242-4250.<br><br />
<span style="color: #475569;">[学术点评]：基因关联。开创性研究，揭示了 MDM2/MDM4 扩增及 EGFR 突变与 HPD 的强相关性，为临床筛选高危人群提供了分子标志物。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[3] <strong>Lo Russo G, et al. (2019).</strong> <em>Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade.</em> <strong>[[Clinical Cancer Research]]</strong>. 2019;25(3):989-999.<br><br />
<span style="color: #475569;">[学术点评]：机制突破。证实了 Fc 受体介导的巨噬细胞重编程是 HPD 的关键机制，解释了为何某些 PD-1 抗体更容易引发 HPD。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[4] <strong>Ferrara R, et al. (2018).</strong> <em>Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.</em> <strong>[[JAMA Oncology]]</strong>. 2018;4(11):1543-1552.<br><br />
<span style="color: #475569;">[学术点评]：大样本验证。在 NSCLC 队列中证实 HPD 确实与免疫治疗特异相关（化疗组无此现象），且与极差的预后显著相关。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
超进展 (HPD) · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">鉴别诊断</td><br />
<td style="padding: 10px 15px; color: #334155;">[[假性进展]] (Pseudoprogression) • [[原发性耐药]] • [[获得性耐药]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">关键分子</td><br />
<td style="padding: 10px 15px; color: #334155;">[[MDM2]] • [[EGFR]] • [[Fcγ受体]] • [[巨噬细胞]] (M2型)</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">计算指标</td><br />
<td style="padding: 10px 15px; color: #334155;">[[TGR]] (肿瘤生长速率) • [[TGK]] (肿瘤生长动力学) • [[ctDNA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 85px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle; white-space: nowrap;">相关药物</td><br />
<td style="padding: 10px 15px; color: #334155;">[[纳武利尤单抗]] • [[帕博利珠单抗]] • [[阿特珠单抗]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
77921020